Naraya Plus (Drospirenone, Ethinylestradiol | Lactose)

Drospirenone, the active ingredient in Naraya Plus, is a combined oral contraceptive presented as an oral tablet for oral use. It works to prevent pregnancy by suppressing ovulation, thickening cervical mucus, and inducing endometrial changes in women of reproductive age.

GNH USA supplies Naraya Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions. Clients benefit from reliable sourcing, transparent pricing, and dedicated technical support throughout the procurement process.

Naraya Plus, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent pregnancy.

- Contraception (prevention of pregnancy): provides reliable hormonal birth control for women of reproductive age. - Menstrual cycle regulation: helps achieve more predictable menstrual periods and reduces cycle‑related symptoms. - Acne improvement: may reduce androgen‑related acne lesions in some users.

Like all hormonal contraceptives, Naraya Plus may be associated with adverse reactions.

Common Side Effects: - Nausea: mild stomach upset often occurring early in treatment. - Headache: tension‑type or migraine‑like headaches. - Breast tenderness: temporary swelling or discomfort. - Spotting or breakthrough bleeding: irregular light bleeding between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Hypertension: significant increase in blood pressure. - Liver dysfunction: abnormal liver enzyme levels or jaundice.

Before prescribing Naraya Plus, clinicians should consider several safety and handling precautions.

- Contraindications: avoid use in women with history of thromboembolic disorders, estrogen‑dependent tumors, or active liver disease. - Smoking: do not prescribe to women over 35 who smoke heavily due to increased cardiovascular risk. - Medication review: assess concurrent use of drugs that affect coagulation or hepatic metabolism. - Monitoring: advise regular blood pressure checks and evaluation for signs of thrombosis. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Naraya Plus can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Combined hormonal contraceptives with other estrogen‑containing products: may increase risk of thrombotic events. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): can markedly reduce contraceptive efficacy.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole): may increase plasma levels of drospirenone. - Antidepressants (e.g., sertraline): may affect bleeding patterns. - Herbal supplements containing St John’s wort: may decrease hormonal levels and reduce contraceptive reliability.